Cargando…

Haemodynamic effects of riociguat in CTEPH and PAH: a 10-year observational study

BACKGROUND: Long-term treatment with riociguat has been shown to enhance exercise capacity in patients with pulmonary arterial hypertension (PAH) and inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH). This study sought to evaluate the long-term haemodynamic eff...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Suqiao, Yang, Yuanhua, Zhang, Yixiao, Kuang, Tuguang, Gong, Juanni, Li, Jifeng, Li, Yidan, Wang, Jianfeng, Guo, Xiaojuan, Miao, Ran
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2021
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419318/ https://www.ncbi.nlm.nih.gov/pubmed/34513985 http://dx.doi.org/10.1183/23120541.00082-2021

Ejemplares similares

Expression of miR-93-5p as a Potential Predictor of the Severity of Chronic Thromboembolic Pulmonary Hypertension
por: Gong, Juanni, et al.
Publicado: (2021)

Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH
por: Gall, Henning, et al.
Publicado: (2018)

Switching to riociguat: a potential treatment strategy for the management of CTEPH and PAH
por: Benza, Raymond L., et al.
Publicado: (2020)

The Role of Strain by Cardiac Magnetic Resonance Imaging in Predicting the Prognosis of Patients with Chronic Thromboembolic Pulmonary Hypertension
por: Zhang, Xuefei, et al.
Publicado: (2023)

Padua prediction score may be inappropriate for VTE risk assessment in hospitalized patients with acute respiratory conditions: A Chinese single-center cohort study()
por: Yang, Suqiao, et al.
Publicado: (2023)

Switching from sildenafil to riociguat for the treatment of PAH and inoperable CTEPH: Real-life experiences
por: Andersen, Asger, et al.
Publicado: (2017)

Cell landscape atlas for patients with chronic thromboembolic pulmonary hypertension after pulmonary endarterectomy constructed using single-cell RNA sequencing
por: Miao, Ran, et al.
Publicado: (2021)

Single-cell RNA-sequencing and microarray analyses to explore the pathological mechanisms of chronic thromboembolic pulmonary hypertension
por: Miao, Ran, et al.
Publicado: (2022)

hsa-miR-106b-5p participates in the development of chronic thromboembolic pulmonary hypertension via targeting matrix metalloproteinase 2
por: Miao, Ran, et al.
Publicado: (2020)

Riociguat dose titration in patients with chronic thromboembolic pulmonary hypertension (CTEPH) or pulmonary arterial hypertension (PAH)
por: Ghofrani, Hossein A, et al.
Publicado: (2009)

Riociguat in Patients with CTEPH and Advanced Age and/or Comorbidities
por: Barnikel, Michaela, et al.
Publicado: (2022)

Efficacy and Safety of Bronchial Artery Embolization on Hemoptysis in Chronic Thromboembolic Pulmonary Hypertension: A Pilot Prospective Cohort Study
por: Yang, Suqiao, et al.
Publicado: (2019)

Analysis of clinical and imaging features of Behcet's disease-related pulmonary lesions: a series of eight cases
por: Zhang, Bingjie, et al.
Publicado: (2022)

Local and Systemic RAGE Axis Changes in Pulmonary Hypertension: CTEPH and iPAH
por: Moser, Bernhard, et al.
Publicado: (2014)

Refractory pleural effusion as a rare complication of pulmonary vascular stenosis induced by fibrosing mediastinitis: a case report and literature review
por: Yang, Suqiao, et al.
Publicado: (2021)

Beneficial effects of riociguat on hemodynamic responses to exercise in CTEPH patients after balloon pulmonary angioplasty – A randomized controlled study
por: Aoki, Tatsuo, et al.
Publicado: (2020)

Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension
por: Kim, Nick H, et al.
Publicado: (2017)

Diagnostic value of miRNA expression and right ventricular echocardiographic functional parameters for chronic thromboembolic pulmonary hypertension with right ventricular dysfunction and injury
por: Miao, Ran, et al.
Publicado: (2022)

Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trial( )
por: Dachs, Theresa Marie, et al.
Publicado: (2022)

Non-invasive evaluation of hemodynamics in pulmonary hypertension by a Septal angle measured by computed tomography pulmonary angiography: Comparison with right-heart catheterization and association with N-terminal pro-B-type natriuretic peptide
por: TANG, QIANG, et al.
Publicado: (2013)

Microarray expression profile of circular RNAs in chronic thromboembolic pulmonary hypertension
por: Miao, Ran, et al.
Publicado: (2017)

Longitudinal strain correlated with haemodynamics in patients with chronic thromboembolic pulmonary hypertension
por: Liu, Min, et al.
Publicado: (2016)

Microarray Analysis and Detection of MicroRNAs Associated with Chronic Thromboembolic Pulmonary Hypertension
por: Miao, Ran, et al.
Publicado: (2017)

Riociguat for pulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD): A subgroup analysis from the PATENT studies
por: Stephan, Rosenkranz, et al.
Publicado: (2015)

Right Ventricular Function and Its Coupling With Pulmonary Circulation in Precapillary Pulmonary Hypertension: A Three-Dimensional Echocardiographic Study
por: Li, Yidan, et al.
Publicado: (2021)

NOVEL CTEPH MIMICKERS IN THE COVID-19 ERA
por: Pietrowicz, Rylie, et al.
Publicado: (2022)

Left ventricular strain in patients with Takayasu arteritis with preserved ejection fraction: an analysis using cardiac magnetic resonance imaging feature tracking
por: Guo, Xiaojuan, et al.
Publicado: (2022)

Variation of PetCO(2) during incremental exercise and severity of IPAH and CTEPH
por: Sun, Xingxing, et al.
Publicado: (2022)

Symptoms, impacts, and suitability of the Pulmonary Arterial Hypertension – Symptoms and Impact (PAH-SYMPACT™) questionnaire in patients with chronic thromboembolic pulmonary hypertension (CTEPH): a qualitative interview study
por: Currie, Brooke, et al.
Publicado: (2021)

Riociguat: PATENT-1 Study
por: Said, Karim
Publicado: (2014)

Central versus Peripheral CTEPH—Clinical and Hemodynamic Specifications
por: Kaldararova, Monika, et al.
Publicado: (2022)

Cardiopulmonary exercise testing and pulmonary function testing for predicting the severity of CTEPH
por: Zhu, Hanqing, et al.
Publicado: (2021)

Right Ventricular Function Predicts Adverse Clinical Outcomes in Patients With Chronic Thromboembolic Pulmonary Hypertension: A Three-Dimensional Echocardiographic Study
por: Li, Yidan, et al.
Publicado: (2021)

Ambrisentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
por: Escribano-Subias, Pilar, et al.
Publicado: (2019)

Epidemiology of chronic thromboembolic pulmonary hypertension (CTEPH) in the Czech Republic
por: Jansa, Pavel, et al.
Publicado: (2022)

Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat
por: Frey, Reiner, et al.
Publicado: (2017)

Real-Time Three-Dimensional Echocardiography to Assess Right Ventricle Function in Patients with Pulmonary Hypertension
por: Li, Yidan, et al.
Publicado: (2015)

Pulmonary artery sarcoma presenting as chronic thromboembolic pulmonary hypertension (CTEPH)
por: Ampatzidou, Fotini, et al.
Publicado: (2023)

Echocardiographic characteristics of pulmonary artery involvement in Takayasu arteritis
por: Jiang, Wei, et al.
Publicado: (2017)

Effects of riociguat in severe experimental pulmonary hypertension
por: Kojonazarov, Baktybek, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_r2goj2jotrf7fdqb36vdpm83ob